MBX — MBX Biosciences, Inc. Common Stock stock price, charts and financials
QT92MBX Biosciences, Inc. Common StockMBX Biosciences, Inc. Common Stock (NASDAQ: MBX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 47.60M | Perf Week | 6.59% |
| Market Cap | 2.99B | Forward P/E | - | EPS next Y | -4.03 | Insider Trans | -0.12% | Shs Float | 20.70M | Perf Month | -8.03% |
| Enterprise Value | 2.58B | PEG | - | EPS next Q | -0.84 | Inst Own | - | Short Float | 8.73% | Perf Quarter | 46.20% |
| Income | -87.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 5.50 | Perf Half Y | 121.28% |
| Sales | 0.00 | P/B | 7.30 | EPS next Y | -29.88% | ROA | -23.93% | Short Interest | 4.16M | Perf YTD | 99.46% |
| Book/sh | 8.61 | P/C | 7.15 | EPS next 5Y | - | ROE | -26.01% | 52W High | 72.64 -13.39% | Perf Year | 532.90% |
| Cash/sh | 8.80 | P/FCF | - | EPS past 3/5Y | - | ROIC | -28.56% | 52W Low | 9.66 551.24% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.11% 4.37% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -30.27% | Oper. Margin | 0.00% | ATR (14) | 3.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.08 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 50.61 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.08 | EPS Q/Q | -34.48% | SMA20 | -0.05% | Beta | 1.41 | Target Price | 80.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -1.16% | Rel Volume | 1.42 | Prev Close | 63.89 |
| Employees | 63 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | 49.32% | Avg Volume | 655.14K | Price | 62.91 |
| IPO Date | Sep 13, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -23.32% - | Net Debt/EBITDA | 0.47 | Volume | 932,359 | Change | -1.53% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-10-26 | Reiterated | Truist Securities | Buy | $70 → $88 |
| Aug-07-26 | Reiterated | Barclays | Overweight | $70 → $88 |
| Jul-23-26 | Reiterated | UBS | $60 → $90 | |
| May-12-26 | Reiterated | Stifel Nicolaus | $50 → $56 | |
| May-12-26 | Reiterated | Barclays | Overweight | $66 → $70 |
| May-11-26 | Reiterated | Truist Securities | Buy | $50 → $70 |
| Mar-09-26 | Reiterated | Truist Financial | $50 | |
| Jan-27-26 | Initiated | Barclays | Overweight | $66 |
| Jan-16-26 | Reiterated | Guggenheim | Buy | $44 → $88 |
| Jan-07-26 | Reiterated | UBS | $60 |
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | |
| Gross Profit | 0 | 0 | 0 | — | |
| Selling, General and Administrative Excl. Other | 19 | 11 | 7 | — | |
| Research and Development | 79 | 57 | 29 | — | |
| Other Operating Expense | 0 | 0 | -1 | — | |
| Operating Income | -98 | -68 | -35 | — | |
| Interest Expense | 0 | 0 | 0 | — | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 11 | 6 | 3 | — | |
| Net Income Before Taxes | -87 | -62 | -33 | — | |
| Income Taxes | 0 | 0 | 0 | — | |
| Consolidated Net Income | -87 | -62 | -33 | — | |
| Net Income From Continuing Operations | -87 | -62 | -33 | — | |
| Net Income | -87 | -62 | -33 | — | |
| EPS (Recurring) | -2.38 | -1.85 | -1.02 | — | |
| EPS (Basic, Before Extraordinaries) | -2.38 | -1.85 | -1.02 | — | |
| EPS (Diluted) | -2.38 | -1.85 | -1.02 | — | |
| EBITDA | -87 | -62 | -32 | — | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | |
| Gross Margin | — | — | — | — | |
| Operating Margin | — | — | — | — | |
| Net Margin | — | — | — | — | |
| Shares Outstanding | 37 | 33 | 32 | — | |
| Market Capitalization | 1,167 | 608 | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Azoulay Salomon | Chief Medical Officer | Aug 04 '26 | Sale | 65.77 | 370 | 24,335 | 14,399 | Aug 05 |
| Azoulay Salomon | Chief Medical Officer | May 08 '26 | Option Exercise | 11.65 | 140,006 | 1,630,696 | 194,540 | May 11 |
| Azoulay Salomon | Chief Medical Officer | May 08 '26 | Sale | 38.36 | 70,003 | 2,685,515 | 14,769 | May 11 |
| Hawryluk P. Kent | President & CEO | May 06 '26 | Sale | 29.54 | 607 | 17,931 | 727,667 | May 08 |
| Azoulay Salomon | Chief Medical Officer | May 06 '26 | Sale | 29.54 | 231 | 6,824 | 14,769 | May 08 |
| Hawryluk P. Kent | President & CEO | Mar 13 '26 | Buy | 28.41 | 18,500 | 525,663 | 486,777 | Mar 16 |
| Hawryluk P. Kent | President & CEO | Feb 26 '26 | Option Exercise | 16.00 | 28,768 | 460,288 | 728,274 | Feb 27 |
| Hawryluk P. Kent | President & CEO | Oct 24 '25 | Option Exercise | 3.25 | 182,859 | 594,292 | 664,256 | Oct 28 |
| Hawryluk P. Kent | President & CEO | Oct 20 '25 | Buy | 13.64 | 20,000 | 272,790 | 468,277 | Oct 21 |
| Hoerter Steven L. | Director | Oct 17 '25 | Buy | 13.25 | 20,000 | 264,984 | 20,000 | Oct 20 |
| Heron Patrick J | director, 10 percent owner: | Sep 26 '25 | Buy | 18.00 | 666,666 | 11,999,988 | 5,219,440 | Sep 30 |
| Pescovitz Ora H. | Director | Apr 08 '25 | Buy | 5.89 | 7,693 | 45,312 | 24,329 | Apr 10 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Feb 18 '25 | Buy | 10.84 | 143,170 | 1,551,963 | 3,255,000 | Feb 19 |
| GORDON CARL L | director, 10 percent owner: | Feb 18 '25 | Buy | 10.84 | 143,170 | 1,551,963 | 3,255,000 | Feb 19 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Feb 14 '25 | Buy | 9.87 | 47,502 | 468,793 | 3,205,930 | Feb 19 |